Cyclin D1 expression and novel mutational findings in Rosai‐Dorfman disease
暂无分享,去创建一个
[1] Marilyn M. Li,et al. SETD2 mutations in primary central nervous system tumors , 2018, Acta neuropathologica communications.
[2] J. Manning,et al. Focal Rosai–Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation , 2018, Modern Pathology.
[3] S. Shrikhande,et al. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview , 2018, Current genomics.
[4] S. Vicent,et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target , 2018, Molecular Cancer.
[5] C. Fletcher,et al. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling , 2018, Modern Pathology.
[6] J. Jagannathan,et al. Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib. , 2017, The New England journal of medicine.
[7] Lin Sun,et al. Cyclin D1 expression by histiocytes may mimic cyclin D1-positive proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma. , 2017, Pathology, research and practice.
[8] Joseph D Khoury,et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease , 2017, Modern Pathology.
[9] G. Pinkus,et al. Cyclin D1 Is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations , 2017, The American journal of surgical pathology.
[10] A. Tripathi,et al. ICUS/CCUS/CHIP: basics & beyond , 2017, Expert review of hematology.
[11] O. Abdel-Wahab,et al. Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. , 2017, Hematology/oncology clinics of North America.
[12] I. Tabbara,et al. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances. , 2017, Anticancer research.
[13] D. Cooper,et al. The NF1 somatic mutational landscape in sporadic human cancers , 2017, Human Genomics.
[14] Monia Magliozzi,et al. Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome , 2017, Human mutation.
[15] C. Classen,et al. The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches , 2016, Klinische Pädiatrie.
[16] C. Hutter,et al. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies , 2016, ImmunoTargets and therapy.
[17] P. Gimotty,et al. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia , 2016, PloS one.
[18] B. Reva,et al. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking , 2014, Clinical Cancer Research.
[19] Larissa V Furtado,et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. , 2014, Blood.
[20] K. Gatter,et al. Immunohistological recognition of cyclin D1 expression by non‐lymphoid cells among lymphoid neoplastic cells , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[21] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[22] M. Borrello,et al. TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells , 2011, Oncogene.
[23] W. Hahn,et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.
[24] A. Bagg,et al. Coexisting follicular and mantle cell lymphoma with each having an in situ component: A novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma. , 2010, American journal of clinical pathology.
[25] Sarah Edkins,et al. Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.
[26] X. Estivill,et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients , 2003, Journal of medical genetics.
[27] H. Stöhr,et al. A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. , 1995, Human molecular genetics.
[28] A. Paller,et al. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras‐ERK pathway mutations , 2018, Journal of the American Academy of Dermatology.